Opinion|Videos|October 2, 2024 (Updated: October 2, 2024)
Commentary on Redefining Depression Management with Updated Treatment Strategies
A panel of depressive disorder experts examines the need for updated APA treatment guidelines related to major depressive disorder, highlighting the roles of pharmacotherapy, psychotherapy, and combination therapy based on severity.
Advertisement
Episodes in this series
Advertisement
Related to this article
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
2
Vol 43, Issue 9 - Interactive
3
Debunking the Top 10 Misleading Claims About Antidepressants
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5